Dallas, TX -- (SBWIRE) -- 02/27/2014 -- After a more than decade long dormancy, the Obesity market is undergoing a revival with the advent of several novel therapies that will lend considerable visibility to this indication space. This includes the use of combination therapies that simultaneously target multiple pathways and regulate appetite control, as well as novel molecular entities with new mechanisms of action. Due to this growing pipeline of late-stage drugs, this market is expected to experience substantial growth over the next decade.
New US entrants are expected to obtain significant market share during the forecast period, as this is a key potential market with an obese population exceeding that of Europe, Japan, and Canada combined. With a severely underserved market, any new players will most certainly have a large potential patient share to gain. The expected drivers of market growth are an increased awareness of the importance of preemptive treatment and sustained management of the condition.
Complete report of UK Obesity Drug Market is available @ http://www.rnrmarketresearch.com/pharmapoint-obesity-uk-drug-forecast-and-market-analysis-to-2022-market-report.html .
Although the prevalence of obesity in the UK is one of the highest among the EU countries, it is a severely underserved market, with Xenical and its generic being the sole therapies for chronic weight management. Due to the high cost of therapy, most patients have been taking generic orlistat. In the UK, overweight and obesity are traditionally treated with lifestyle modifications, such as dietary regulation and increased physical activity.
Overview of Obesity including epidemiology, etiology, symptoms, diagnosis, pathology and treatment guidelines as well as an overview on the competitive landscape.
Detailed information on the key drugs in the UK and US including product description, safety and efficacy profiles as well as a SWOT analysis.
Sales forecast for the top drugs in the UK and US from 2012-2022.
Analysis of the impact of key events as well the drivers and restraints affecting the UK and US Obesity market.
Complete report of US Obesity Drug Market is available @ http://www.rnrmarketresearch.com/pharmapoint-obesity-us-drug-forecast-and-market-analysis-to-2022-market-report.html
Reasons to buy
Understand and capitalize by identifying products that are most likely to ensure a robust return.
Stay ahead of the competition by understanding the changing competitive landscape for Obesity.
Effectively plan your M&A and partnership strategies by identifying drugs with the most promising sales potential.
Make more informed business decisions from insightful and in-depth analysis of drug performance.
Obtain sales forecast for drugs from 2012-2022 in the UK and US.
Google Plus: https://plus.google.com/u/0/104156468549256253075/posts